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Abstract: Rhenium-188 is a useful radionuclide for targeted therapy thanks to the high energy (2.12 MeV) β- emission, 
low abundance gamma rays (155 keV and 15%) suitable for imaging and availability from the 188W/188Re generator. 
Though considerable amount of work on the development of 188Re-radiopharmaceuticals have been reported in the 
literature, the clinical uses of them are still low mainly due to the limited availability and high cost of the generators. 
However, a 188Re radiopharmacy can be successfully run provided the generator is used for the preparation of several 
188Re-radiopharmaceuticals. The relatively low radioactive concentration of 188Re from conventional alumina based 
generators, thereby needing post elution concentration, is one of the limitations for the extended use of the generator. 
The development of nanomaterials having higher capacity for adsorption of 188W allows it to be used for the preparation 
of column generators capable of giving high radioactive concentration for the eluted perrhenate. This review provides an 
overview of the work done at the Bhabha Atomic Research Centre, Mumbai, India, for the development of 188W/188Re 
generator as well as the development of several 188Re-based radiopharmaceuticals. 
Keywords: Nanomaterials, Radionuclide generator, Radiopharmaceuticals, Rhenium-188, Targeted therapy. 
1. INTRODUCTION 
Rhenium belongs to the group 7 of the periodic 
table, same as that of 99mTc, the workhorse of nuclear 
medicine. Rhenium has two important radioisotopes, 
186Re [half-life – 3.71 days, Eβmax – 1.09 MeV, Eγ - 136 
keV (9%)] and 188Re [half-life – 16.9 h, Eβmax – 2.12 
MeV, Eγ - 155 keV (15%)][1], both of which have beta 
energies suitable for therapy and gamma emissions, 
though of low abundance, which permits monitoring the 
distribution of the radiotracer in vivo, and potentially, 
perform image-based dosimetry calculations. While 
relatively low-energy beta particles of 186Re are useful 
for therapeutic applications requiring low tissue 
penetration, high-energy beta from 188Re are 
particularly useful for therapy of diseases in large 
organs such as liver. Being in the same group of the 
periodic table, technetium and rhenium share similar 
chemistry, which implies, wherever applicable, it is 
possible to have theranostic pair with 99mTc and 
186/188Re radionuclides. However, rhenium being more 
difficult to reduce than technetium, quite often, 
technetium chemistry cannot be directly extrapolated 
for preparing rhenium radiopharmaceuticals. Rhenium 
generally requires harsher radiolabeling conditions 
compared to technetium, and therefore, ligands that  
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cannot survive these conditions cannot be used for 
preparing rhenium radiopharmaceuticals.  
Rhenium-186 is a reactor-produced radionuclide 
from neutron activation of enriched 185Re or natural 
rhenium. A difficulty associated with the production of 
186Re from natural rhenium is the co-production of 
188Re. Though mixed radiation therapy with 186/188Re is 
feasible, the approach has not been further pursued. 
On the other hand, 188Re is a decay product of long 
lived 188W and hence available from a 188W/188Re 
generator. Like the 99Mo/99mTc generator, which has a 
major role in making 99mTc the workhorse of nuclear 
medicine, 188W/188Re generator has the potential to 
popularize the use of 188Re-radiopharmaceuticals for 
therapy. 
Commercial availability of 188W/188Re generator has 
a significant role to play in popularizing the use of 
188Re-radiopharmaceuticals in nuclear medicine. An 
equally important aspect is to make available new 
188Re-radiopharmaceuticals and freeze dried kits for 
their preparation in hospital radiopharmacy housing the 
188W/188Re generator. In this review, authors have 
attempted to cover the recent developments in 
188W/188Re generator technology and discuss some of 
the important 188Re-radiopharmaceuticals, which have 
been used in the clinic or which have clinical potential. 
These discussions are mainly focused on the 
developmental activities done at the Bhabha Atomic 
Research Centre, India. 
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2. DISCUSSION 
2.1. Nanosorbents for 188W/188Re Generator Prepa- 
ration  
188W/188Re generator is an excellent source for 
availing no-carrier-added (NCA) grade 188Re. Most of 
the separation methodologies which have been 
reported for 99Mo/99mTc generators have also been 
exploited for preparation of 188W/188Re generators [2]. 
Out of these procedures, the alumina based column 
chromatographic approach wherein 188W is absorbed 
on bulk alumina matrix and 188Re is selectively eluted 
using saline solution at regular intervals, has been 
identified as the most reliable method for the 
preparation of 188W/188Re generator. Owing to the 
limited sorption capacity of bulk alumina (~50 mg W/g), 
clinical-scale 188W/188Re generator can only be 
prepared using high specific activity (150-190 GBq/g) 
188W that can be produced in only very few high flux 
(~1015 n.cm-2.s-1) reactors available (High Flux Isotope 
Reactor at Oak Ridge National Laboratory in United 
States and SM Reactor at Dimitrograd in Russia) in the 
world. Even while using high specific activity 188W 
produced in these reactors, the 188W/188Re generators 
currently available yield low specific volume (activity/ 
mL) of 188Re and require post-elution concentration 
procedures prior to radiopharmaceutical preparation, 
which is not always very convenient to perform in 
hospital radiopharmacies [3]. From this perspective, it 
is desirable to develop a 188W/188Re generator where 
the concentration step can be avoided to simplify the 
operational procedure for widespread clinical utility. 
Use of nanomaterials as adsorbents for 188W/188Re 
generator holds promise as they take advantage of the 
unique physiochemical properties realized at nanoscale 
that cannot be anticipated from bulk counterparts of the 
same chemical composition. The defining feature of a 
nanomaterial is that its properties depend not only on 
composition but also on its size and shape. One of the 
specific properties of this class of material is that a high 
percent of the atoms lies on the surface and the 
material possesses high surface area. These surface 
atoms are unsaturated and possess high chemical 
activity. Therefore, such materials demonstrate high 
sorption capacity and enhanced selectivity for 188W 
resulting in elution of 188Re with adequate radioactive 
concentration and high radionuclidic purity. The above 
properties make nanomaterials an exciting platform to 
develop into the realm of 188W/188Re generator 
technology with properties that are difficult to achieve 
using bulk materials.  
The ability of three nanomaterial based sorbents 
(nanocrystalline titania (TiP), zirconia (ZrO2) and 
alumina (γ-Al2O3)) have been comprehensively studied 
and profusely explored for the development of 
188W/188Re generators by our group [4-7]. Taking 
advantage of the new physical properties uniquely 
associated with nanomaterials, 188W/188Re generators 
were prepared using 188W having specific activity of 3-5 
Ci/g. A scrutiny of the results depicted in Table 1 
reveals that all these sorbents are suitable for 
preparation of 188W/188Re generators. Though testing of 
these nanomaterials was done by using lower load of 
188W, the capacity of the generator can easily be scaled 
up to >37 GBq (1 Ci) activity levels as the capacity of 
the nanomatarials are very high. Among all the 
sorbents used, γ-Al2O3 was found to exhibit the highest 
sorption capacity under dynamic conditions as 
compared to TiP and ZrO2 and is therefore the most 
appropriate sorbent for the preparation of clinical-scale 
188W/188Re generator. The performance of these 
generators was studied for more than 6 months and 
reported to be satisfactory. Not only were the 188Re 
elution yields appreciably high but also the level of 
radionuclidic, radiochemical and chemical impurities in 
the 188Re obtained from all these generators were well 
within the acceptable limits prescribed in the 
pharmacopoeias [8].  
The mechanism of uptake of 188W and elution of 
188Re from the nanosorbent based chromatographic 
columns could be explained on the basis of pH 
dependent surface charge on nanosorbents. There are 
various anionic species of tungsten depending on the 
pH of the medium. At pH 6, the predominant species is 
W12O4110- and between pH 2 and 4 the species 
W12O396- predominates. Owing to electrostatic 
attraction, highly negatively charged tungsten anion is 
taken up on the positively charged surface of the 
nanosorbent under mildly acidic conditions. 
Subsequently, it may form a stable complex of the type 
[AlW6O24]8-, similar to that reported for bulk alumina. As 
these tungstate ions start transforming into perrhenate 
ion (188ReO4-), which has only the mononegative 
charge, the binding gets weaker and an easy 
displacement of 188ReO4- is expected from the 
nanosorbent. 
The performance of the 188W/188Re generators 
prepared using nanomaterial based sorbents is 
comparable with conventional alumina based 
generators in terms of 188Re elution yield and the purity 
of the eluate. However, due to higher sorption capacity 
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of nanomaterials, relatively lower specific activity 188W 
produced in medium flux research reactors can also be 
used for preparation of clinical-scale 188W/188Re 
generators while using such materials as the sorbent 
matrix. It is also pertinent to point out that 
agglomerated nanomaterials (comprising of nanosized 
crystallites) are used as sorbents for preparation of 
radionuclide generators. Typically, the size of the 
agglomerates is in the range of 50-100 mesh size (149-
297 µm), which is comparable to the size of bulk 
alumina particles used in preparation of conventional 
generators. Controlled agglomeration of nanoparticles 
is essential in order to use them as sorbents for 
radionuclide generators, as fully dispersed 
nanoparticles would exhibit issues such as increased 
back pressure during the elution process and might 
also result in breakthrough of nanoparticles in the 188Re 
eluate. While using agglomerated nanomaterial based 
sorbents, no change in the generator design and the 
elution procedure is required. 
Adoption of nanosorbents (especially γ-Al2O3) for 
preparation of 188W/188Re generator would reduce 
reliance on the two high flux reactors for 188W-
production. There are a number of research reactors in 
the world having thermal neutron flux >5 × 1014 n cm-2 
s-1 which could be used for the production of 188W for 
making 188W/188Re generators. Also if the existing 
generator manufacturers can shift to γ-Al2O3 as 
adsorbent, the generator capacity can be increased. 
Simultaneously the activity per mL can also be 
increased by using smaller bed size for the column and 
lower volume of eluent.  
2.2. 188Re Based Radiopharmaceuticals 
The Radiopharmaceuticals Division of the Bhabha 
Atomic Research Centre has been carrying out 
research on the development of 188Re 
radiopharmaceuticals for over 25 years. The following 
sections give details of some of the important 
developments. 
2.3. 188Re(V)DMSA (DMSA – Dimercapto Succinic 
Acid) 
99mTc(V)DMSA is a widely used radiopharma- 
ceutical for diagnostic imaging of medullary carcinoma 
of thyroid [9-11], head and neck tumors, [12, 13], soft 
tissue tumors and metastatic bone lesions and osseous 
metastasis from breast cancer [14-16]. Rhenium being 
the therapeutic analogue of 99mTc, which shares similar 
chemistry, envisaging use of 186/188Re(V)DMSA for 
therapeutic applications is obvious. Bisunadan et al. 
reported the first study on the preparation and use of 
186Re(V)DMSA for tumor therapy [17]. Subsequently, 
several others reported the preparation and use of 
186/188Re(V)DMSA for different cancers [18-20]. General 
approach for the preparation of 186/188Re(V)DMSA 
involves heating DMSA with Na186/188ReO4 in presence 
of Sn2+ at 100°C. Following this method, Kothari et al. 
reported the preparation of 186Re(V)DMSA and its 
biological evaluation in Wistar rats [21]. They observed 
significant uptake of the radiotracer in kidneys, which 
limited wide spread application of this therapeutic agent 
in the clinic. Attempts to reduce the kidney uptake of 
186/188Re(V)DMSA using blocking agents were not 
successful [22]. Later, Kothari et al. found that signify- 
cant reduction in kidney uptake of 186/188Re(V)DMSA 
could be achieved by modifying the method of 
preparation of the radiotracer. The 186/188Re(V)DMSA 
prepared using sodium metabisulphite (Na2S2O5) as 
reducing agent in place of stannous chloride (SnCl2), 
showed significant reduction in kidney uptake (only 
0.68±0.06 %ID/g at 24 h post injection (p.i.)). It is 
pertinent to note that kidney uptake observed with 
186/188Re(V)DMSA prepared by conventional method, 
using stannous chloride as reducing agent, was 
2.93±0.93 %ID/g at the same time point [23]. Though 
the reason for this observation was not understood, 
authors observed a noticeable change in the isomeric 
ratio of the 186/188Re(V)DMSA complex. The high-
performance liquid chromatography (HPLC) analysis of 
186/188Re(V)DMSA prepared by conventional method 
using stannous chloride as reducing agent showed 
three major peaks representing anti, syn-endo and syn-
Table 1: Summary of 188W/188Re Generators Developed Using Nanosorbents 
Sorbent 
Dynamic 
Sorption 
Capacity (mg/g) 
Activity of 
188W Loaded 
(GBq) 
Elution 
Yield of 
188Re (%) 
Maximum Radioactive 
Concentration of 188Re 
(GBq/mL) 
Level of 188W 
Impurity in 
188Re (%) 
Radiochemical 
Purity of 
188ReO4- (%) 
Consistency 
in Generator 
Performance 
TiP 100 1.85 > 80 0.37 < 10-3 >99 
ZrO2 120 1.85 > 78 0.33 < 10-4 >99 
γ-Al2O3 326 11.1 > 80 1.85 < 10-3 >99 
Consistent 
performance 
for 6 months 
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exo isomers, respectively, as shown in Figure 1(A) 
[24]. Apart from these major peaks, a minor peak 
representing an unknown structure was observed 
between the anti and syn-endo isomeric forms. Kothari 
et al. observed significant contribution from this peak in 
186/188Re(V)DMSA prepared using sodium metabi- 
sulphite reducing agent [Figure 1(B)] [23]. However, it 
is not clear whether it has any correlation with 
reduction in kidney uptake and the phenomenon is 
worth investigating. 
Recently, our group developed a lyophilized kit for 
the preparation of 188Re(V)DMSA at room temperature 
[unpublished results]. It is known that presence of 
oxalate facilitate reduction of rhenium, therefore the 
room temperature kit (RT kit) contained sodium oxalate 
in addition to other ingredients of conventional kit, i.e. 
DMSA and stannous chloride. Using this kit 
188Re(V)DMSA could be prepared in >98% yield at 
room temperature in 15 min. Though HPLC analysis of 
188Re(V)DMSA prepared using RT kit showed similar 
isomeric peak patterns, the isomeric ratios were 
different. The 188Re(V)DMSA prepared following the 
conventional method, by heating at 100°C for 30 min, 
had the anti, syn-endo and syn-exo isomers in the ratio 
48:39:13, whereas, the 188Re(V)DMSA prepared using 
RT kit at room temperature had the isomeric ratios 
48:29:23, respectively. It is interesting to note that 
experimental conditions had effect only on the syn-
endo and syn-exo isomeric ratio and percentage 
contribution from the anti isomer remained same. This 
apparently small change in the isomeric ratio of 
188Re(V)DMSA prepared using RT kit, however, had 
profound influence on the overall biodistribution pattern 
in Swiss mice bearing fibrosarcoma tumor. With 
188Re(V)DMSA prepared following conventional 
method, we observed uptake in bone (15 %ID/g), 
kidney (3.2 %ID/g) and tumor (2.2 %ID/g) at 60 min p.i. 
Subsequently, the activity cleared from all organs and 
at 24 h p.i., the activity in bone, kidney and tumor were 
2.8 %ID/g, 1.5 %ID/g and 0.2 %ID/g, respectively. 
Similarly, biodistribution of 188Re(V)DMSA prepared 
using RT kit showed initial uptake of 6 %ID/g, 1.8 
%ID/g and 1.4 %ID/g in bone, kidney and tumor, 
respectively, at 60 min p.i. It could be noted that uptake 
values in these organs/tissue are relatively lower 
compared to the distribution of 188Re(V)DMSA 
prepared by conventional method at the same time 
point. However, at 24 h p.i. a significant increase in 
bone uptake (22 %ID/g) was observed, while the 
uptake values in kidney (1.2 %ID/g) and tumor (0.4 
%ID/g) were similar to that of 188Re(V)DMSA prepared 
by conventional method.  
In another experiment, 188Re(V)DMSA prepared 
using RT kit was heated at 100°C for 10 min. 
Subsequent HPLC analysis of the sample revealed that 
isomeric ratios changed from 48:29:23 to 48:38:14, 
which was very close to that of 188Re(V)DMSA 
prepared using conventional kit. This experiment 
possibly indicated higher thermodynamic stability of 
syn-endo isomer vis-à-vis syn-exo isomer. Proceeding 
further, we carried out biodistribution of 188Re(V)DMSA 
prepared by RT kit at room temperature and then 
heating it again at 100°C for 10 min. As expected, the 
biodistribution results were similar to the one obtained 
with 188Re(V)DMSA prepared by conventional method. 
These results indicate that higher bone uptake 
observed in the case of 188Re(V)DMSA prepared using 
RT kit at room temperature may be due to the syn-exo 
isomer. This interesting results advocate further 
investigation to understand the distribution of individual 
 
Figure 1: HPLC elution profile of 186/188Re(V)DMSA prepared using different reducing agents (A) stannous chloride and (B) 
metabisulphite [23]. 
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isomers. If an isomer was found to be suitable for a 
particular application, modification of reaction 
conditions to maximize the yield of that isomer could be 
the next logical step forward. 
2.4. 186/188Re-HEDP (HEDP – Hydroxyethane 1,1-
Diphosphonic Acid) 
186/188Re-HEDP is a clinically established palliating 
agent for bone pain due to osseous metastasis [25-31]. 
Initial HEDP studies were carried out using 186Re 
radioisotope. Rhenium-186 is a reactor produced 
radioisotope from neutron radiative capture (n,γ) 
reaction on enriched 185Re or natural rhenium (37.4% 
enriched in 185Re). 
Kothari et al. reported preparation and evaluated 
186Re-HEDP from 186Re produced from natural rhenium 
[32]. This was probably the first study, which used 
186Re produced from natural rhenium in a medium flux 
(6 x 1013 neutrons/cm2/s) reactor. The 186Re-HEDP 
prepared under optimized conditions (pH - 2, 
SnCl2.2H2O - 10 mg, HEDP – 50 mg, reaction 
temperature - 100ºC, time – 30 min) was evaluated in 
normal Wistar rats. The distribution study showed 
significant uptake of 186Re-HEDP in bone (30.7 ± 0.04 
%ID/organ at 3 h p.i.) and retention thereafter, 
throughout the duration of the study (29.5 ± 4.0 
%ID/organ at 48 h p.i.). There was no significant 
uptake of activity in any other major organs. During 
optimization studies, authors observed that >98% 
radiochemical purity could be achieved with HEDP 
amount as low as 1.25 mg/mL, stannous chloride  
0.4 mg and total rhenium content 100 µg, rest of the 
reaction conditions remaining the same. However, to 
achieve stability of 186Re-HEDP for extended periods, 
significantly higher amounts of the reactants were 
necessary. This observation was in agreement with a 
study reported by Elder et al., which established the 
influence of amounts of HEDP, stannous chloride and 
the total rhenium content on the final structure of Re-
HEDP, and consequently, its biodistribution [33]. Use of 
natural rhenium resulted in, unavoidable, co-production 
of 188Re (Half-life – 16.9 h). Therefore, the authors 
cooled the irradiated sample for four days to reduce the 
activity of 188Re to ~6% of the total activity. Authors 
noticed, and highlighted, the practical difficulty with this 
approach of 186Re-HEDP preparation, since it resulted 
in significant reduction in 186Re-activity during the 
cooling period. By this approach, preparation of clinical 
dose of 186Re-HEDP was virtually impractical. As an 
alternative, authors proposed mixed radionuclide 
therapy with 186/188Re-HEDP, which could eliminate the 
4 day cooling requirement. However, dosimetry of 
mixed radionuclide therapy approach with 186/188Re-
HEDP was challenging, which probably limited its 
clinical applications. 
With commercial availability of 188W/188Re 
generator, several studies using 188Re-HEDP were 
reported. A comparative clinical study of 188Re-HEDP, 
186Re-HEDP, 153Sm-EDTMP and 89Sr by Liepe et al. 
demonstrated similar efficacy of these agents for 
palliation of pain from osseous metastasis [30]. The 
authors concluded that efficacy being comparable, 
choice of therapeutic radionuclide may be decided 
based on availability of the radioisotope and logistics. 
In this respect, 188Re-HEDP enjoyed clear advantage 
over the other pain-palliating agents based on reactor 
produced radioisotopes, since it can be prepared on 
demand in any hospital radiopharmacy housing a 
188W/188Re generator. 
The growth of nuclear medicine can be partly 
attributed to the availability of lyophilized 
radiopharmaceutical kits and 99Mo/99mTc generator. For 
a hospital radiopharmacy having a 188W/188Re 
generator, availability of lyophilized kits for the 
preparation of 188Re-radiopharmaceuticals is an 
advantage. Verdera et al. reported the first lyophilized 
kit for the preparation 188Re-HEDP [35]. Preparation of 
188Re-HEDP requires addition of carrier rhenium to 
carrier-free Na188ReO4 from 188W/188Re generator. This 
is essential to obtain the 188Re-HEDP species which 
shows the pharmacokinetics necessary for a bone pain 
palliating agent. Along with HEDP (10 mg), gentisic 
acid (3 mg) and stannous chloride dihydrate (3.7 mg), 
Verdera et al., included carrier potassium perrhenate 
(300 µg, ~1 µmol) in their lyophilized HEDP kit. Though 
the authors have not mentioned the shelf-life of such 
lyophilized HEDP kits, presence of stannous and 
carrier perrhenate together in the kit could significantly 
shorten the shelf-life of the kit. 
Mallia et al. circumvented this problem of short 
shelf-life of the kit by excluding the carrier perrhenate 
from the HEDP kits [36]. While rest of the kit 
components and their amounts remained similar to that 
of the kit reported by Verdera et al., preparation of 
188Re-HEDP using this kit required addition of 1µmol of 
carrier perrhenate along with freshly eluted Na188ReO4 
from 188W/188Re generator. Subsequently, heating the 
kit vial at 100°C for 20 min resulted in the formation of 
188Re-HEDP in more than 98% radiochemical purity. 
After adjusting the pH of the preparation to 
physiological conditions (using sterile sodium acetate 
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provided with the kit), the preparation is ready for 
patient administration. Shelf-life of this kit was one year 
from the date of production. Clinical evaluation of 
188Re-HEDP prepared using these kits are being 
carried out in different nuclear medicine centres in 
India. The development of lyophilized HEDP kit in 
BARC is well-timed considering the increasing number 
of nuclear medicine centres in India offering 188Re-
therapy. 
2.5. 188ReN-DEDC/Lipiodol (DEDC – Diethyl Dithio- 
carbamate) 
Hepatocellular carcinoma (HCC) is the most 
common primary liver cancer and represents the 
second most common causes of cancer death 
worldwide [37]. Patients presented with late stage 
HCC, which are unresectable, are recommended for 
loco-regional therapies such as transarterial 
chemoembolization (TACE), selective internal radiation 
therapy (SIRT) or sorafinib therapy, depending on the 
stage of the disease [38]. SIRT is also called TARE or 
transarterial radioembolization. TARE is similar to 
TACE, the only difference being the use of radiation 
emitted from radioisotopes for therapy in former, while 
the latter uses chemotherapeutics. TARE using 
radiolabelled particles and colloids are one of the 
options for inoperable HCC patients. There are several 
options for doing TARE, which include 90Y-labeled 
particulates based on glass (TheraSphere®) or resin 
(SIR-Spheres®) and 131I- or 188Re-labeled lipiodol. 
Especially in India, high cost of 90Y-microspheres and 
non-availability of local substitutes has limited this 
mode of therapy to a very small group of patients who 
can afford it.  
Wang et al. reported the preparation of 188Re-
labeled lipiodol for TARE [39]. Their approach involved 
preparation of 188Re-EDTB (EDTB - N,N,N",N"-
tetrakis(2-benzymidazolylmethyl)-l,2-ethanediamine) 
and subsequent incubation with EDTB-lipiodol at 70ºC 
for 2h. This procedure resulted in 188Re-lipiodol >98% 
yield. Biodistribution studies carried out in Sprague 
Dawley rats showed slow clearance of activity from 
liver, however, accumulation of significant levels of 
activity in lungs and kidneys severely limited its clinical 
applications. 
Jeong et al. reported preparation and use of a 
lipiodol solution of 188Re-TDD (TDD - 2,2,9,9-
Tetramethyl-4,7-diaza-1,10-decanedithiol) for therapy 
of liver cancer [40]. This method involved preparation 
of a lipophilic complex, 188Re-TDD, and subsequent 
extraction into lipiodol. Due to the lipophilic nature of 
the 188Re-TDD complex, it is retained in lipiodol phase. 
This radioactive lipiodol solution was used for TARE 
procedure. Though 188Re-TDD could be prepared in 
good yields and extracted into lipiodol, authors noticed 
that its retention in liver is not good enough to treat liver 
cancer patients. The same group subsequently 
reported a modified form of 188Re-TDD, 188Re-HDD 
(HDD - 4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-
decanedithiol), which showed higher retention in liver. 
Kumar et al. reported an IAEA-sponsored clinical study, 
which concluded that TARE with 188Re-HDD is safe 
and effective option for the therapy of inoperable 
hepatocellular carcinoma [41]. Lyophilized kits for the 
preparation of 188Re-HDD are available commercially.  
Although, 188Re-HDD complex could be prepared in 
high yields with commercially available kits, extraction 
of the complex into the lipiodol phase was not 
satisfactory. Boschi et al. reported preparation of a 
lipiodol solution of 188ReN-DEDC (DEDC – diethyl 
dithiocarbamate) complex [42]. This approach was very 
similar to that of Jae Min Jeong et al. wherein a 
lipophilic 188Re-complex was prepared and extracted 
into lipiodol. The complex 188ReN-DEDC is prepared in 
two steps. First step involved preparation of 188Re-
nitrido core, which was subsequently used for 
radiolabeling DEDC ligand to obtain 188ReN-DEDC 
complex. By this method, 188ReN-DEDC complex could 
be prepared in >97% radiochemical purity and >96% 
extraction of the complex into lipiodol could be 
achieved. Clinical trials with 188ReN-DEDC/lipiodol 
showed retention of activity in liver with no activity 
accumulation seen in lungs, kidneys or any other vital 
organs. 
Considering increasing number of liver cancer 
incidences in India, a need for locally available, 
effective and economical TARE agent was felt. 
Following the procedure reported by Prof. Duatti’s 
group, we developed a two-vial kit for the preparation 
of 188ReN-DEDC. First kit vial used for the preparation 
of 188ReN core, contained 2 mg of DTCz (N-methyl-S-
methyl-dithiocarbazate), 28 mg of sodium oxalate and 
0.8 mg of stannous chloride dihydrate. The second kit 
contained 27 mg of DEDC and carbonate buffer (1 M). 
The procedure involved addition of up to 3 mL of 
freshly eluted Na188ReO4 containing 150 µL of glacial 
acetic acid to the kit vial 1. Upon incubating at room 
temperature for 30 min, 188ReN core could be prepared 
in >90% yield. In the second step, kit vial 2 was 
reconstituted with 2 mL of sterile saline and 1.5 mL of 
the solution is aseptically transferred to kit vial 1. 
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Subsequently, kit vial 1 was heated at 70ºC for 20 min 
to obtain 188ReN-DEDC complex. Analysis of the 
reaction mixture showed that 188ReN-DEDC complex 
was formed in >80% purity. In the third step, 1-2 mL of 
sterile lipiodol was added to kit vial 1, the contents 
were thoroughly mixed for 5 min and subsequently 
centrifuged for 10 min to effect separation of the two 
layers. The lipiodol layer containing the 188ReN-DEDC 
complex was carefully separated and used for TARE. 
The SPECT/CT images obtained during preliminary 
clinical trials using 188ReN-DEDC/lipiodol, carried out in 
Tata Memorial Hospital, Mumbai, showed retention of 
the 188Re-activity in liver 24 h p.i., with no detectable 
accumulation of activity in lungs or kidneys. A 
regulatory clearance to manufacture and supply the kits 
in India is underway. 
2.6. 188Re-Agents for Radiation Synovectomy 
Radiation synovectomy is an effective treatment for 
rheumatoid arthritis [43-46]. This modality, which is an 
alternative to surgical intervention, involves intra-
articular injection of beta emitting radiopharmaceutical 
to control the synovial inflammation. A critical 
requirement of radiation synovectomy agents is their 
ability to localize at the point of injection, since leaching 
of the agent will render the therapy ineffective. A 
general approach to minimize the effect of leaching is 
to use a short-lived radioisotope such that therapeutic 
dose can be delivered at the point of inflammation in a 
short span of time. Another approach to minimize 
leaching is to use radiolabeled particles with larger size 
[47]. 
Yttrium-90 and 32P are two radioisotopes commonly 
used for the preparation of synovectomy agents [48, 
49]. Both radioisotopes have high-energy beta 
emissions suitable for synovectomy applications. 
However, being pure beta emitters, both radioisotopes 
exclude the possibility of imaging to assess localization 
of the injected radiopharmaceutical. Additionally, the 14 
day half-life of 32P is too long and in the event of 
leaching it may result in radiation dose to other 
organs/tissues. In this context, 188Re has significant 
advantages over both 90Y and 32P, owing to its 
favorable physical and chemicals properties described 
in section 1. Additionally, it has relatively short half-life 
(16.9 hours) and it is a generator produced 
radioisotope. Preparation and evaluation of 188Re 
labeled microspheres and 188Re-suphur colloids was 
reported earlier [50-53]. However, significant leaching 
from the site of injection severely limited their 
application. Hydroxyl apatite (HA), a major component 
of the bone matrix, had been radiolabeled with 186/188Re 
for synovectomy applications [54, 55]. However, these 
agents exhibited poor in vitro stability, which limited 
their application. 
Kothari et al. reported direct labeling of HA with 
188Re [47]. Their method involved incubation of freshly 
eluted Na188ReO4 with HA (10 mg), sodium oxalate (10 
mg) and stannous chloride (10 mg) at room 
temperature for 1 hour. The pH of the solution was 
maintained at 1.4 using hydrochloric acid. 
Subsequently, the 188Re-HA particles were washed 
with ascorbic acid to remove free perrhenate and re-
suspended in ascorbic acid medium. By this method, 
188Re-HA particles could be prepared in >98% yield. 
Authors observed that presence of oxalate significantly 
reduced the dissolution of HA under acidic conditions. 
Particle size of cold Re-HA, determined by laser 
diffraction, was found to be between 2-20 µm (>90%). 
188Re-HA particles were found to be stable in ascorbic 
acid medium for up to 4 days. Upon intraarticular 
injection of 188Re-HA particles in rat joints, extra-
articular leakage of only 2.5% was observed even after 
2 days post injection. Overall, this study demonstrated 
the potential of 188Re-HA particles for therapy of 
inflamed synovial joints. 
2.7. Miscellaneous 188Re-Radiopharmaceuticals 
2.7.1. 188Re-Skin Patches 
Application of radioactive skin patches is an 
effective mode of therapy for skin cancers and 
superficial tumors [56]. This modality is an alternative 
to teletherapy, brachytherapy or kilo voltage x-ray 
therapy for the treatment of superficial cancers. Papers 
or skin patches incorporating beta emitting 
radionuclides such as 188Re or 166Ho has been reported 
earlier [57-59]. 
Mukharjee et al. reported a modified procedure for 
the preparation of 188Re-bandage patch [60]. Their 
method involved preparation of 188Re-tin colloid 
followed by trapping of the radioactive colloidal particle 
on to a 0.22 µm Millipore filter by passing the solution 
through the filter. The filter paper was subsequently 
sandwiched between two nitrocellulose membranes 
and then placed on an adhesive bandage for 
therapeutic applications. Radioactive bandages thus 
prepared were evaluated in melanoma tumor bearing 
C57BL/6 mice. The study conclusively demonstrated 
the efficacy and potential of 188Re-bandages for the 
therapy of superficial tumors [Figure 2]. 
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Figure 2: Control mouse (A) bearing melanoma (25 day old 
tumor); and mouse treated with skin patch application after 
five months (B) [60]. 
2.7.2. 188Re-EC (EC-Ethylene Dicystene) for 
Endovascular Therapy 
Restenosis is an event with significant probability 
following coronary angioplasty [61, 62]. One of the 
procedures followed to avoid/minimize restenosis of 
dilated artery by balloon angioplasty is by local delivery 
of radiation dose to the dilated arteries [63-65]. Dose 
delivery is generally achieved using balloon filled with 
radioactive solution by a procedure similar to balloon 
angioplasty. One of the inherent risks in this procedure 
is the rupture of balloon during the procedure leading to 
leakage of the radioactive liquid into circulation. 
Therefore, the pharmacokinetics of the radiotracer 
should be such that in the event of a balloon rupture, 
the activity should clear from the body within a short 
period of time, such that dose burden on the patient 
could be minimized. A comparison between 
Na188ReO4, 188Re-MAG3 and 188Re-DTPA for this 
application revealed that 188Re-MAG3 is most suitable 
for the purpose [64]. However, the long-term stability of 
188Re-MAG3 is doubtful [66].  
Das et al. [67] reported the preparation of 186/188Re- 
EC, an analogue of 99mTc-EC, which is a clinically used 
renal agent, as a substitute for 188Re-MAG3. Optimized 
procedure for the preparation of 186/188Re-EC involved 
incubation of a mixture of 10 mM solution of EC with 
stannous chloride (2 mg) and Na186/188ReO4 at 100ºC 
for 20 min. The pH of the reaction mixture was 
maintained at 2. By this method, 188Re-EC could be 
prepared in >98% radiochemical purity. Biodistribution 
studies of 186/188Re-EC carried out in Wistar rats 
indicated that in terms of clearance and dose delivered 
to other vital organs, 186/188Re-EC had distinct 
advantages over other rhenium agents used for 
endovascular brachy therapy applications. In addition, 
186/188Re-EC was also found to retain its radiochemical 
purity for a longer time compared to 188Re-MAG3. 
2.7.3. 186Re-CTMP (CTMP – 1,4,8,11-Tetraaza Cyclo- 
tetradecyl-1,4,8,11-Tetramethylene Phosphonic 
Acid) for Bone Pain Palliation 
Phosphonates have shown good affinity for bone 
matrix and they have been utilized to deliver 
therapeutic dose of radiation to pain causing metastatic 
or primary bone lesions to obtain palliative effect to the 
patients. A number of phosphonates radiolabeled with 
beta emitting radionuclides such as 186Re, 188Re, 
153Sm, 177Lu etc. have been prepared and evaluated 
[25-34]. A number of such phosphonate radiopharma- 
ceutials are in clinical use today. 
Kothari et al. had earlier reported the preparation 
and evaluation of 186/188Re-HEDP for bone pain 
palliation [32]. The same group reported synthesis, 
radiolabeling and evaluation of a cyclic phosphonate 
for bone pain palliation [68]. Starting from cyclam 
(1,4,8,11-tetraaza cyclotetradecane), formaldehyde 
and orthophosphoric acid, a tetra phosphonate ligand, 
1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetrame- 
thylene phosphonic acid or CTMP, was synthesized. 
This ligand was subsequently radiolabeled with 
Na186ReO4 by heating at 100ºC for 30 min in presence 
of stannous chloride as reducing agent. The pH of the 
reaction mixture was maintained at 2. By this 
procedure, 186Re-CTMP could be prepared in >97% 
RCP. Authors observed that 186Re-CTMP complex 
remained stable at room temperature for up to 6 days 
post preparation. Biodistribution of 186Re-CTMP in 
normal Wistar rats showed significant uptake and 
retention of the complex in skeleton with fast clearance 
from other non-target organs. A comparison with 186Re-
HEDP indicated that the pharmacokinetic parameters 
of 186Re-CTMP are either similar or superior to the 
former [Figure 3]. Overall, 186Re-CTMP complex 
demonstrated its potential as a possible bone pain-
palliating agent. 
2.7.4. 186/188Re-Labeled Porphyrin for Targeted 
Radiotherapy 
Porphyrin is a structural unit central to the oxygen 
transporter in our body, the hematoporphyrin. 
Porphyrins have shown preferential accumulation in 
neoplastic tissues, lymph nodes, embryonic and 
traumatized tissues [69-72]. This property made them 
potential molecules for diagnosis and therapy of 
various diseases such as cancer [69-77]. Wong et al. 
reported a 99mTc-hematoporphyrin for in vivo imaging 
applications [78]. In this complex, 99mTc was tagged at 
the periphery of the porphyrin ring. Thereafter, several 
studies were reported wherein different derivatives of 
porphyrins were radiolabeled with radioisotopes such 
Nanomaterial Sorbents for the Preparation of 188W/188Re Generator International Journal of Nuclear Medicine Research, 2017    75 
as 57Co, 64Cu, 109Pd etc. [79-81]. A notable difference 
between the 99mTc-hematoporphyrin and the 
57Co/64Cu/109Pd-porphyrins is that in the latter, the 
metal atom (57Co, 64Cu or 109Pd) occupied the centre of 
the porphyrin ring. However, 57Co/64Cu/109Pd-porphyrin 
derivatives failed to show selective uptake in target 
tissue. This observation possibly indicates that the 
porphyrin significantly lose its ability to accumulate in 
tumor ones a metal atom occupy its core. 
Banerjee et al. reported the synthesis of a water-
soluble porphyrin, meso-tetrakis[3,4-bis(carboxy 
methyleneoxy)phenyl] porphyrin, and subsequently 
radiolabeled it with 186/188Re [82]. Radiolabeling was 
carried out under basic conditions (pH 9) in presence of 
stannous tartarate as reducing agent. Upon heating the 
reaction mixture at 100ºC for 30 min, the 186/188Re-
porphyrin complex could be prepared in >98% yield. 
Biodistribution studies of 186/188Re-porphyrin complex in 
Swiss mice bearing fibrosarcoma tumor showed uptake 
in tumor (~3.5% ID/g), and retention till the duration of 
the study (24 h). Authors observed no significant 
accumulation of activity in any other vital organ. Major 
clearance of activity was through renal route. 
CONCLUSIONS 
Availability of radionuclides at affordable cost is one 
of the important considerations for the growth of 
nuclear medicine. The initial investments needed to 
start a program and adequate revenue returns from it 
are prime considerations. Considering relatively high 
cost of 188W/188Re generator it is important to use the 
generator for as many applications as possible. 
Therefore, improving 188Re-radiopharmaceutical 
portfolio is highly essential. Despite the fact that the 
rhenium radiopharmaceuticals development program 
was initiated at the Bhabha Atomic Research Centre in 
the early nineties, clinical utility was limited due to the 
lack of interest shown by nuclear medicine 
departments. A new fillip to the program was provided 
by the entry of Kovai Institute of Medical Sciences 
(KMCH) which started the routine clinical use of 
188W/188Re generator for the treatment of HCC and a 
collaborative program between BARC and KMCH. One 
of the newer developments thanks to this collaboration 
is the development of lyophilized DEDC kits for the 
preparation of 188ReN-DEDC/lipiodol for the therapy of 
inoperable HCC. Along with lyophilized DEDC kits, 
other lyophilized kits for the preparation of 188Re-
HEDP, 188Re-DMSA etc. will help in effective utilization 
of 188Re-activity from 188W/188Re generator. The authors 
also feel it appropriate that the commercial 
manufacturers explore the utility of high capacity 
adsorbents discussed in this paper for making 
generators with higher load of 188W which will provide 
high activity per mL for the eluted perrhenate solution.  
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